CALQUENCE

vs ibrutinib

Get ready for new data

Head-to-head data vs ibrutinib will be available soon. Don't miss the ASCO oral presentation on June 7th at 11:30 AM CDT

Days

Hours

Minutes

Seconds

Sign up to learn more

Get ready for new data

Head-to-head data vs ibrutinib will be available soon. Don't miss the ASCO oral presentation on June 7th at 11:30 AM CDT

Days

Hours

Minutes

Seconds

Sign up to learn more

Explore more about CALQUENCE for your patients with CLL

ASCO=American Society of Clinical Oncology; CLL=chronic lymphocytic leukemia.

Indication and Usage

Indication and Usage

CALQUENCE is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

Select Safety Information

Serious adverse events, including fatal events, have occurred with CALQUENCE, including serious and opportunistic infections, hemorrhage, cytopenias, second primary malignancies, and atrial fibrillation and flutter. The most common adverse reactions (≥ 30%) of any grade in patients with CLL were anemia, neutropenia, thrombocytopenia, headache, upper respiratory tract infection, and diarrhea.

Please see full Prescribing Information, including Patient Information.